Resources

PACE has launched its second funding round, with up to £5 million available to support cutting-edge diagnostic projects. This funding is part of a broader £30 million investment to address the global challenge of AMR.

LinkGevity, an AI-driven drug discovery company focused on longevity and age-related disease, announces its selection for the highly competitive SPACE-H Accelerator program, powered by Starburst in collaboration with NASA’s Human Research Program (NASA HRP), the Translational Research Institute for Space Health (TRISH), and Microsoft Federal (Microsoft).

It’s a back-to-school feel with a bang for me this week as the landscape of the Association’s work til Christmas comes into sharp focus. Read on for our proposals for a sector-by-sector approach to analyse the effectiveness of R&D tax reliefs, turning health into economic growth, pandemics and more!

This year RNID have been chosen as the BIA’s charity partner of the year. This partnership gives us a unique platform to shine the light on the huge opportunities that exist for hearing therapeutics.

At the recent International Society for Stem Cell Research (ISSCR) Annual Meeting in Hamburg, ACROBiosystems announced its new GMP-centered brand, Resilient Supply, with the mission of accelerating the advancement of cell and gene therapy (CGT) development.

Molly Andrews of the UK Dementia Research Institute, Priya Kalia of SciTribe, and Miranda Weston-Smith of BioBeat highlight the urgent need for innovative digital solutions and investments in the accurate diagnosis and effective treatment of neurodegenerative diseases, as emphasised at BioBeat24.

Engitix Ltd announced the appointment of two biotech industry leaders as Scientific Advisors: Adrian S. Ray, PhD, and Scott Turner, PhD.

ACROBiosystems, a global cornerstone of the pharmaceutical industry committed to offering innovative tools and solutions, announces the launch of GMP grade DLL4. GMP grade DLL4 is the first recombinant Delta-like Ligand 4, or DLL4, to be launched on the market under GMP conditions.

New draft legislation was published last week on the UK’s R&D tax regime, which will continue to support innovative life sciences and biotech companies to conduct essential clinical trials and some pre-clinical work overseas. The campaign has been covered in Research Professional. The legislation, yet to be approved by Parliament, follows the announcement by the former Chancellor, Rishi Sunak MP, that the regime would be amended to end payments for R&D conducted overseas to “refocus” it on innovation in the UK.

The experience of the pandemic has underscored the importance of clinical trials in the rapid development of the medicines needed to improve global health. During the COVID-19 vaccine development process, the UK adopted faster and leaner processes for rolling out clinical trials without compromising patient safety. Using what we learned from the pandemic as our ‘peacetime’ norm would have a hugely positive impact on meeting patient needs faster and at a lower financial cost.